This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Molina Healthcare (MOH), Cencora (COR)

Tipranks - Tipranks - Tue May 12, 5:32AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Molina Healthcare (MOH), Cencora (COR) and Nuvalent (NUVL) with bullish sentiments.

Claim 55% Off TipRanks

Molina Healthcare (MOH)

Bank of America Securities analyst Kevin Fischbeck maintained a Buy rating on Molina Healthcare today and set a price target of $250.00. The company’s shares closed last Friday at $185.94.

According to TipRanks.com, Fischbeck is a 2-star analyst with an average return of 0.7% and a 56.9% success rate. Fischbeck covers the Healthcare sector, focusing on stocks such as Ardent Health Partners, Inc., Universal Health, and Encompass Health. ;'>

Molina Healthcare has an analyst consensus of Hold, with a price target consensus of $165.23, a -14.4% downside from current levels. In a report issued on May 8, TipRanks – PerPlexity also upgraded the stock to Buy with a $213.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Cencora (COR)

In a report released yesterday, Stephen Baxter from Wells Fargo maintained a Buy rating on Cencora, with a price target of $331.00. The company’s shares closed last Friday at $261.08.

According to TipRanks.com, Baxter is a 3-star analyst with an average return of 1.1% and a 47.5% success rate. Baxter covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., BrightSpring Health Services, Inc., and Molina Healthcare. ;'>

Cencora has an analyst consensus of Strong Buy, with a price target consensus of $353.78, which is a 39.2% upside from current levels. In a report issued on May 7, TipRanks – Google also upgraded the stock to Buy with a $283.00 price target.

Nuvalent (NUVL)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Nuvalent, with a price target of $155.00. The company’s shares closed last Friday at $105.28, close to its 52-week high of $113.51.

According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 19.9% and a 45.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Actuate Therapeutics, Inc., Janux Therapeutics Inc, and Unicycive Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nuvalent with a $141.23 average price target, a 36.9% upside from current levels. In a report issued on April 27, Stifel Nicolaus also maintained a Buy rating on the stock with a $135.00 price target.

Read More on MOH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).